Pneumologie 2023; 77(08): 550-553
DOI: 10.1055/a-2095-3321
Original Article

Point-of-care procalcitonin testing for lower respiratory tract infection in pulmonary outpatient care has limited value

Die ambulante Anwendung von Point-of-care-Procalcitonin-Test bei Infekten der unteren Atemwege ist nur eingeschränkt hilfreich
David Raupach
1   Respiratory medicine and Infectious disease, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)
,
Oana Joean
1   Respiratory medicine and Infectious disease, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)
,
Jan Fuge
2   Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany (Ringgold ID: RIN9177)
3   BREATH, German Center for Lung Research, Hannover, Germany (Ringgold ID: RIN542891)
,
Tobias Welte
2   Klinik für Pneumologie, Medizinische Hochschule Hannover, Hannover, Germany (Ringgold ID: RIN9177)
,
Jessica Rademacher
1   Respiratory medicine and Infectious disease, Hannover Medical School, Hannover, Germany (Ringgold ID: RIN9177)
› Author Affiliations
Supported by: ThermoFisher

TRIAL REGISTRATION: Registration number (trial ID): 8736_MPG_23b2019, Trial registry: ClinicalTrials.gov (http://www.clinicaltrials.gov/) NCT05380869, Type of Study: Prospective Observational

Abstract

Lower respiratory tract infections (LRTI) are frequently the reasons for patients to visit their general practitioners or lung specialists; however, physicians tend to prescribe antibiotics less frequently than necessary. A readily available biomarker could help distinguish between viral and bacterial cause of LRTI. The primary objective of our study was to determine the diagnostic accuracy of point-of-care testing (POCT) of procalcitonin (PCT) in identifying bacterial pneumonia in outpatients with LRTI. All patients aged 18 years or older with signs and symptoms of LRTI who visited a respiratory physician were included in the study and their PCT levels were measured. In 110 patients enrolled in the study, three patients (2.7%) had PCT values above the threshold of 0.25 µg/L without proven bacterial infection, in contrast to seven patients with typical radiological signs of pneumonia without elevated POCT PCT levels. The AUC for PCT for the detection of pneumonia was 0.56 (p=0.685). POCT PCT showed limited specificity and sensitivity in distinguishing pneumonia from bronchitis or exacerbation of chronic respiratory diseases. PCT is a marker of severe bacterial infections and not suitable for milder infections in outpatient care.

Zusammenfassung

Infektionen der unteren Atemwege sind ein häufiger Grund zur Vorstellung beim Allgemeinmediziner oder Pneumologen und führen nicht selten zu einer inadäquaten Antibiotika-Therapie. Ein sofort verfügbarer Biomarker zur Unterscheidung einer viralen von einer bakteriellen Genese des Infektes könnte helfen Antibiotika einzusparen. Das Ziel unserer Studie war die Prüfung der diagnostischen Aussagekraft eines POCT PCT in Bezug auf die bakterielle Pneumonie im ambulanten Setting. Alle erwachsenen Patienten mit Zeichen einer Infektion der unteren Atemwege und Vorstellung beim Pneumologen wurden eingeschlossen. Das PCT wurde mittels Schnelltest gemessen. Von den 110 in die Studie eingeschlossen Patienten wiesen 3 (2,7%) ein erhöhtes PCT (>0,25 µg/L) auf. Keiner von ihnen hatte eine bakterielle Infektion oder wurde mit Antibiotika behandelt. Im Kontrast dazu hatten 7 Patienten mit radiologisch nachgewiesener Pneumonie kein erhöhtes PCT. Die AUC für PCT zur Detektion einer Pneumonie lag bei 0,56, p=0,685. Das POCT PCT zeigte damit nur eine eingeschränkte Sensitivität und Spezifität in der Unterscheidung von Pneumonie zur Bronchitis oder Exazerbation. PCT ist ein Marker für schwere Infektionen und bei eher milden Infektionen, die ambulant behandelt werden können, eingeschränkt hilfreich.



Publication History

Received: 10 March 2023

Accepted after revision: 12 May 2023

Article published online:
14 June 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Anthierens S, Tonkin-Crine S, Cals JW. et al. Clinicians’ views and experiences of interventions to enhance the quality of antibiotic prescribing for acute respiratory tract infections. J Gen Intern Med 2015; 30: 408-416 DOI: 10.1007/s11606-014-3076-6. (PMID: 25373834)
  • 2 Hogendoorn SKL, Lhopitallier L, Richard-Greenblatt M. et al. Clinical sign and biomarker-based algorithm to identify bacterial pneumonia among outpatients with lower respiratory tract infection in Tanzania. BMC Infect Dis 2022; 22: 39 DOI: 10.1186/s12879-021-06994-9.
  • 3 Lhopitallier L, Kronenberg A, Meuwly J-Y. et al. Procalcitonin and lung ultrasonography point-of-care testing to determine antibiotic prescription in patients with lower respiratory tract infection in primary care: pragmatic cluster randomised trial. BMJ 2021; 374: n2132 DOI: 10.1136/bmj.n2132.
  • 4 Ewig S, Kolditz M, Pletz M. et al. Management of Adult Community-Acquired Pneumonia – Update 2021. Pneumologie 2021; 75: 665-729 DOI: 10.1055/a-1497-0693. (PMID: 34198346)
  • 5 Briel M, Schuetz P, Mueller B. et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008; 168: 2000-2007 discussion 2007–2008
  • 6 Schuetz P, Christ-Crain M, Thomann R. et al. Effect of Procalcitonin-Based Guidelines vs Standard Guidelines on Antibiotic Use in Lower Respiratory Tract Infections: The ProHOSP Randomized Controlled Trial. JAMA 2009; 302: 1059 DOI: 10.1001/jama.2009.1297. (PMID: 19738090)
  • 7 Huang DT, Yealy DM, Filbin MR. et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med 2018; 379: 236-249
  • 8 Kamat IS, Ramachandran V, Eswaran H. et al. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am 2020; 70: 538-542
  • 9 Müller B, Harbarth S, Stolz D. et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10 DOI: 10.1186/1471-2334-7-10. (PMID: 17335562)
  • 10 Banerjee R. CON: Procalcitonin does not have clinical utility in children with community-acquired pneumonia. JAC-Antimicrob Resist 2021; 3: dlab152 DOI: 10.1093/jacamr/dlab152.
  • 11 Montassier E, Javaudin F, Moustafa F. et al. Guideline-Based Clinical Assessment Versus Procalcitonin-Guided Antibiotic Use in Pneumonia: A Pragmatic Randomized Trial. Ann Emerg Med 2019; 74: 580-591 DOI: 10.1016/j.annemergmed.2019.02.025. (PMID: 30982631)
  • 12 Gutiérrez-Pizarraya A, León-García MDC, De Juan-Idígoras R. et al. Clinical impact of procalcitonin-based algorithms for duration of antibiotic treatment in critically ill adult patients with sepsis: a meta-analysis of randomized clinical trials. Expert Rev Anti Infect Ther 2022; 20: 103-112 DOI: 10.1080/14787210.2021.1932462. (PMID: 34027785)
  • 13 Oussalah A, Ferrand J, Filhine-Tresarrieu P. et al. Diagnostic Accuracy of Procalcitonin for Predicting Blood Culture Results in Patients With Suspected Bloodstream Infection: An Observational Study of 35,343 Consecutive Patients (A STROBE-Compliant Article). Medicine (Baltimore) 2015; 94: e1774 DOI: 10.1097/MD.0000000000001774. (PMID: 26554775)
  • 14 Burkhardt O, Ewig S, Haagen U. et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36: 601-607 DOI: 10.1183/09031936.00163309. (PMID: 20185423)